Skip to content

Study · Animal study (in vivo) · mouse · 2024

5 results

The AMPK allosteric activator MK-8722 improves the histology and spliceopathy in myotonic dystrophy type 1 (DM1) skeletal muscle.

Ravel-Chapuis A, Fahmi C, Gobin J, Jasmin BJ

FASEB journal : official publication of the Federation of American Societies for Experimental Biology1 Dec 2024Cited by 7 (Europe PMC)

PMID39611312 (opens in a new tab)DOI10.1096/fj.202401145rr (opens in a new tab)PepBankPUB-39611312
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In HSA LR mice, AICAR improved alternative splicing more than MK-8722.

    In plain wordsIn mice with myotonic dystrophy, AICAR improved alternative splicing more than MK-8722.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreaseAlternative splicing correction
    Study

    mousen: not reported in source

    Male and female HSA<sup>LR</sup> mice with myotonic dystrophy type 1
    Comparator
    MK-8722
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated · injection · 1 and 4 weeksAs given in this study (mouse).

    Source sentences

    Summary
    However, the effects of MK-8722 were more modest compared to AICAR.
    2 context sentences
    Summary · context
    Our results show that 1 and 4 weeks of treatment with MK-8722 improves alternative splicing toward wild-type levels in male and female HSALR muscle.
    Summary · context
    We treated male and female HSALR mice for 1 and 4 weeks with a daily injection of the allosteric activator MK-8722, the AMP mimetic AICAR, or vehicle.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In HSA LR mice, AICAR improved muscle histology less than MK-8722.

    In plain wordsIn mice with myotonic dystrophy, AICAR improved muscle tissue structure less than MK-8722.

    Peptide
    AICAR (acadesine)
    Outcome
    DecreaseMuscle histology improvement
    Study

    mousen: not reported in source

    Male and female HSA<sup>LR</sup> mice with myotonic dystrophy type 1
    Comparator
    MK-8722
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated · injection · 4 weeksAs given in this study (mouse).

    Source sentences

    Summary
    In contrast, 4 weeks of treatment with MK-8722 improved muscle histology to a greater extent than AICAR.
    1 context sentence
    Summary · context
    We treated male and female HSALR mice for 1 and 4 weeks with a daily injection of the allosteric activator MK-8722, the AMP mimetic AICAR, or vehicle.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In HSA LR mice, AICAR promoted expression of slower, more oxidative muscle fibers.

    In plain wordsIn mice with myotonic dystrophy, AICAR increased expression of slower muscle fibers that use oxygen.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreaseSlower oxidative muscle fiber expression
    Study

    mousen: not reported in source

    Male and female HSA<sup>LR</sup> mice with myotonic dystrophy type 1
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated · injection · 4 weeksAs given in this study (mouse).

    Source sentences

    Summary
    As expected with AMPK activation, 4 weeks of treatment with MK-8722 and AICAR promoted the expression of slower, more oxidative fibers.
    1 context sentence
    Summary · context
    We treated male and female HSALR mice for 1 and 4 weeks with a daily injection of the allosteric activator MK-8722, the AMP mimetic AICAR, or vehicle.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In HSA LR mice, acute AICAR injections rapidly and transiently increased muscle phospho-AMPK.

    In plain wordsIn mice with myotonic dystrophy, acute AICAR injections rapidly increased muscle phospho-AMPK for a short period.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreaseMuscle phospho-AMPK response
    Study

    mousen: not reported in source

    Male and female HSA<sup>LR</sup> mice with myotonic dystrophy type 1
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated · injection · acuteAs given in this study (mouse).

    Source sentences

    Summary
    Finally, acute injections of MK-8722 and AICAR triggered the rapid and transient increase in phospho-AMPK in muscle.
    1 context sentence
    Summary · context
    We treated male and female HSALR mice for 1 and 4 weeks with a daily injection of the allosteric activator MK-8722, the AMP mimetic AICAR, or vehicle.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In HSA LR mice, peak AMPK phosphorylation was higher with AICAR than with MK-8722.

    In plain wordsIn mice with myotonic dystrophy, AICAR produced higher peak AMPK phosphorylation than MK-8722.

    Peptide
    AICAR (acadesine)
    Outcome
    IncreasePeak AMPK phosphorylation
    Study

    mousen: not reported in source

    Male and female HSA<sup>LR</sup> mice with myotonic dystrophy type 1
    Comparator
    MK-8722
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated · injection · acuteAs given in this study (mouse).

    Source sentences

    Summary
    However, the peak of AMPK phosphorylation was lower with MK-8722 compared to AICAR, thereby explaining the more modest effects of AMPK allosteric activation.
    1 context sentence
    Summary · context
    We treated male and female HSALR mice for 1 and 4 weeks with a daily injection of the allosteric activator MK-8722, the AMP mimetic AICAR, or vehicle.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.